Maxim Group analyst Anthony Vendetti has maintained their neutral stance on JYNT stock, giving a Hold rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anthony Vendetti has given his Hold rating due to a combination of factors influencing The Joint Corp.’s current financial and operational situation. The company’s third-quarter revenue aligned with expectations, indicating some stability, but the decline in system-wide comparable sales and the reduction in sales guidance for 2025 reflect ongoing challenges. Additionally, while the company is making strides in refranchising and cost-saving measures, these efforts are accompanied by uncertainties regarding the sale and restructuring of corporate-owned clinics.
Despite having a solid cash position and no debt, which reduces the need for additional capital, the macroeconomic pressures and the slow pace of refranchising are limiting near-term growth prospects. The transition to a full franchise model is progressing, but the decrease in total clinics year-to-date and the weaker sales performance present concerns. Until there is more clarity on these transitional dynamics and macroeconomic conditions improve, the potential for significant upside remains limited, justifying the Hold recommendation.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $8.00 price target.
JYNT’s price has also changed moderately for the past six months – from $9.940 to $7.670, which is a -22.84% drop .